FDA Warns of Serious Immune Reaction with Seizure/BPD Medicine Lamotrigine (Lamictal)

Overview
The Food and Drug Administration (FDA) is warning that the medicine lamotrigine (Lamictal) for seizures and bipolar disorder can cause a rare but very serious reaction that excessively activates the body’s infection-fighting immune system. This can cause severe inflammation throughout the body and lead to hospitalization and death, especially if the reaction is not diagnosed and treated quickly.
A link to the full communication detailing specific information for health care professionals and a list of FDA-approved GBCAs can be found at www.fda.gov/Drugs/DrugSafety
Released 4/25/2018

1
FDA Drug Information Updates
The FAERS Public Dashboard and its Value to the Pharmaceutical Industry
The FAERS Public Dashboard and its Value to the Pharmaceutical Industry
The FAERS Public Dashboard and its Value to the Pharmaceutical Industry
1
FDA Drug Information Updates
FDA Requires New Class Warnings for All Gadolinium-Based Contrast Agents
FDA Requires New Class Warnings for All Gadolinium-Based Contrast Agents
FDA Requires New Class Warnings for All Gadolinium-Based Contrast Agents
2
FDA Drug Information Updates
FDA Review: Adding LABAs to ICS Treatment Does Not Significantly Increase Serious Asthma Outcomes Risk
FDA Review: Adding LABAs to ICS Treatment Does Not Significantly Increase Serious Asthma Outcomes Risk
FDA Review: Adding LABAs to ICS Treatment Does Not Significantly Increase Serio…
2
FDA Drug Information Updates
The FDA's Adverse Event Reporting System (FAERS) Public Dashboard
The FDA's Adverse Event Reporting System (FAERS) Public Dashboard
The FDA's Adverse Event Reporting System (FAERS) Public Dashboard

Medical Program: FDA Warns of Serious Immune Reaction with Seizure/BPD Medicine Lamotrigine (Lamictal)